OVERVIEW

Biologic Therapies Summit X and Vasculitis 2023 returns to in-person learning, bringing together world leaders in immune-based therapies and addressing cutting-edge topics in immunology and rheumatology. The course begins with a full day devoted to vasculitis, including key issues in the differential diagnosis of vasculitis, CNS vasculitis, ANCA-associated vasculitis, and organ-specific issues in vasculitis. The Biologic Therapies Summit X offers six sessions over two days, and kicks off with a half-day session featuring talks on CAR T-cell therapy, irAEs, precision medicine and the next generation of JAK inhibitors for IMIDs, and advances in complement biology and therapy. We take a deep dive into rheumatoid arthritis, AS, PsA and SpA in the afternoon. Day two addresses infections, COVID-19, co-morbidities with IMIDs, including ILD and cardiovascular risk in immune-mediated diseases, and lupus. We wrap up the Summit with a session devoted to pain management, as we welcome physician, writer, and clinical researcher, Haider Warraich, MD, for an exploration of the social and scientific fundamentals of pain.

NEW THIS YEAR! A half-day session devoted to APPs, with updates on biologics for SpA and RA, factors to consider when choosing biologics, infectious complications of biologics, and an immunology lecture focusing on cytokines.

LEARNING OBJECTIVES

• Describe and critically appraise the immunologic mechanisms of action for targeted therapies and targeted synthetic therapies as they apply to efficacy and safety across the spectrum of immune-mediated inflammatory diseases including PsA, SpA, RA, SLE and vasculitis.
• Outline how precision medicine has been used to manage immune-related adverse events.
• Define advances in complement with rheumatic and immunologic diseases.
• Summarize evidence on COVID-19 and vaccinations and their effects on patients with immune-mediated inflammatory diseases, and describe the implications for clinical practice.
• Critically appraise how Long COVID presents in patients with immune-mediated inflammatory diseases.
• Evaluate comorbidities such as cardiovascular risk and complications associated with immune-mediated diseases.
• Define the clinical differences between type 1 and type 2 lupus.

TARGET AUDIENCE

The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, pharmacists, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

 ACCREDITATION

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 20.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

For more information please visit the official event page.